Investments
4Portfolio Exits
2Partners & Customers
10About Kyowa Kirin
Kyowa Kirin is a global specialty pharmaceutical company based in Japan. They focus on the anti-body technologies in the core therapeutic areas of oncology, nephrology, and immunology.

Want to inform investors similar to Kyowa Kirin about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Kyowa Kirin News
May 30, 2023
News provided by Share this article Share this article Global specialty pharmaceutical company supports Dream Foundation's work to provide comfort, closure, and inspiration at the end of life. BEDMINSTER, N.J. and SANTA BARBARA, Calif., May 30, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin. Ltd., a global specialty pharmaceutical company, has extended its support of Dream Foundation - the only national dream-granting organization for terminally ill adults, fulfilling more than 34,000 final Dreams across the United States and Puerto Rico. The renewed commitment marks the seventh year of Kyowa Kirin and Dream Foundation working together to make final Dreams come true and will extend through 2024. Since their initial partnership in 2017, Kyowa Kirin and Dream Foundation have brought 100 final Dreams to life. These Dreams have been fulfilled in a range of ways, including family vacations to Disneyland® - helping families make final memories to be cherished, to meetings with personal heroes - bringing a sense of completeness and joy, and the provision of tablets and laptops - to reunite loved ones. In addition to making final Dreams come true, the partnership has allowed U.S.-based Kyowa Kirin employees to be directly involved in Dream deliveries, where they meet Dream recipients and their families and celebrate their lives and final Dreams. This dedication aligns with Dream Foundation's mission to fulfill the final Dreams of terminally ill adults and their families, a critical part of end-of-life care. "Kyowa Kirin's continued commitment to our mission is miraculous," says Dream Foundation's Chief Executive Officer, Kisa Heyer. "Year after year, Kyowa Kirin and its employees have shown a dedication and passion for our Dream recipients, delivering Dreams that directly impact and improve the lives of the recipient and their families." Sandy Vaziri, one of Kyowa Kirin's Regional Sales Managers, appears in " Language of Dreams ," a 2020 film by award-winning director Peter Sasowsky, produced by Dream Foundation. The film is a celebration of life itself, what it means to be human and the redeeming power of supporting each other through difficult times. "At Kyowa Kirin, we strive to have a profound impact on patients' lives. That purpose starts with the novel therapies we discover and deliver and extends into the communities we are a part of," says Lauren Walrath, VP, Public Affairs, North America. "Medical advances can help many patients live with and manage disease. But for those who face a terminal diagnosis, we are glad to offer a final chance to spend time with their loved ones, doing something very special. We believe those moments matter a great deal." Dream Recipients must be at least 18 years old, have a life expectancy of twelve months or less, and lack the resources to achieve their Dreams on their own. To apply for a Dream, please visit dreamfoundation.org/how-to-apply . About Dream Foundation: Dream Foundation, the only national dream-granting organization for terminally ill adults, fulfills final Dreams that provide inspiration, comfort and closure at the end of life. With the support of a nationwide network of volunteers, hospices, health care organizations and committed donors, Dream Foundation has served more than 34,000 final Dreams since its inception in 1994. Dream Foundation receives no state or federal funding—we rely solely on private donations. To support our mission please visit DreamFoundation.org/donate . About Kyowa Kirin Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a more than 70-year heritage, the company applies cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients across multiple therapeutic areas such as nephrology, oncology, immunology/allergy, and neurology. Across its four regions – Japan, Asia Pacific, North America and EMEA/International – Kyowa Kirin focuses on its purpose, to make people smile, and is united by its shared values of commitment to life, teamwork, innovation, and integrity. Learn more about Kyowa Kirin North America at https://kkna.kyowakirin.com/ . SOURCE Dream Foundation
Kyowa Kirin Investments
4 Investments
Kyowa Kirin has made 4 investments. Their latest investment was in Ring Therapeutics as part of their Series C on March 3, 2023.

Kyowa Kirin Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
3/9/2023 | Series C | Ring Therapeutics | $86.5M | Yes | Alexandria Venture Investments, Altitude Life Science Ventures, CJ Investment, Flagship Pioneering, Invus Group, Kyowa Kirin, Partners Investment, T. Rowe Price, Undisclosed Investors, and UPMC Enterprises | 2 |
11/26/2019 | Corporate Minority - P2P | |||||
1/11/2010 | Partnership | |||||
9/23/2007 | Series A - II |
Date | 3/9/2023 | 11/26/2019 | 1/11/2010 | 9/23/2007 |
---|---|---|---|---|
Round | Series C | Corporate Minority - P2P | Partnership | Series A - II |
Company | Ring Therapeutics | |||
Amount | $86.5M | |||
New? | Yes | |||
Co-Investors | Alexandria Venture Investments, Altitude Life Science Ventures, CJ Investment, Flagship Pioneering, Invus Group, Kyowa Kirin, Partners Investment, T. Rowe Price, Undisclosed Investors, and UPMC Enterprises | |||
Sources | 2 |
Kyowa Kirin Portfolio Exits
2 Portfolio Exits
Kyowa Kirin has 2 portfolio exits. Their latest portfolio exit was Solasia Pharma on March 23, 2017.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
3/23/2017 | IPO | Public | 1 | ||
Date | 3/23/2017 | |
---|---|---|
Exit | IPO | |
Companies | ||
Valuation | ||
Acquirer | Public | |
Sources | 1 |
Kyowa Kirin Acquisitions
1 Acquisition
Kyowa Kirin acquired 1 company. Their latest acquisition was Archimedes Pharma on July 11, 2014.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
7/11/2014 | Acquired | 1 |
Date | 7/11/2014 |
---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 1 |
Kyowa Kirin Partners & Customers
10 Partners and customers
Kyowa Kirin has 10 strategic partners and customers. Kyowa Kirin recently partnered with MEI Pharma on July 7, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
7/18/2022 | Licensor | United States | In April 2020 , MEI Pharma , Inc. and Kyowa Kirin entered a global license , development , and commercialization agreement to further develop and commercialize zandelisib . | 2 | |
6/30/2022 | Licensor | Switzerland | AMSTERDAM , June 30 , 2022 / PRNewswire / -- Synaffix , a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates -LRB- ADC Therapeutics 's -RRB- with best-in-class therapeutic index , today announces that Kyowa Kirin -LRB- Kyowa Kirin , TSE : 4151 -RRB- , a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies , has expanded the license agreement with Synaffix -LRB- announced in August 2021 -RRB- by adding a third ADC Therapeutics target to its research evaluation and development efforts under this deal . | 1 | |
6/30/2022 | Licensor | Netherlands | AMSTERDAM , NETHERLANDS -- June 30 , 2022 -- Synaffix , a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates -LRB- ADC 's -RRB- with best-in-class therapeutic index , today announces that Kyowa Kirin -LRB- Kyowa Kirin , TSE : 4151 -RRB- , a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies , has expanded the license agreement with Synaffix -LRB- announced in August 2021 -RRB- by adding a third ADC target to its research evaluation and development efforts under this deal . | 1 | |
6/4/2022 | Licensor | ||||
5/18/2022 | Partner |
Date | 7/18/2022 | 6/30/2022 | 6/30/2022 | 6/4/2022 | 5/18/2022 |
---|---|---|---|---|---|
Type | Licensor | Licensor | Licensor | Licensor | Partner |
Business Partner | |||||
Country | United States | Switzerland | Netherlands | ||
News Snippet | In April 2020 , MEI Pharma , Inc. and Kyowa Kirin entered a global license , development , and commercialization agreement to further develop and commercialize zandelisib . | AMSTERDAM , June 30 , 2022 / PRNewswire / -- Synaffix , a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates -LRB- ADC Therapeutics 's -RRB- with best-in-class therapeutic index , today announces that Kyowa Kirin -LRB- Kyowa Kirin , TSE : 4151 -RRB- , a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies , has expanded the license agreement with Synaffix -LRB- announced in August 2021 -RRB- by adding a third ADC Therapeutics target to its research evaluation and development efforts under this deal . | AMSTERDAM , NETHERLANDS -- June 30 , 2022 -- Synaffix , a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates -LRB- ADC 's -RRB- with best-in-class therapeutic index , today announces that Kyowa Kirin -LRB- Kyowa Kirin , TSE : 4151 -RRB- , a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies , has expanded the license agreement with Synaffix -LRB- announced in August 2021 -RRB- by adding a third ADC target to its research evaluation and development efforts under this deal . | ||
Sources | 2 | 1 | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.